Disc Medicine Inc

Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize treatments for serious hematologic diseases. It currently has no product revenue. Its candidates target two fundamental pathways of red blood cell biology: heme biosynthesis and iron homeostasis.

The pipeline includes:
- **Bitopertin:** an oral GlyT1 inhibitor that modulates heme synthesis. It is being developed for erythropoietic protoporphyria (EPP), where it met all primary and secondary endpoints in the Phase 3 APOLLO trial. An NDA resubmission is planned by end of 2026, with an FDA decision expected by mid-2027.
- **Selcodebart (DISC-0974):** an anti-hemojuvelin antibody that suppresses hepcidin. It is in development for anemia of myelofibrosis (heading toward pivotal development) and inflammatory bowel disease (Phase 2).
- **DISC-3405:** an anti-TMPRSS6 antibody that induces hepcidin. It is being studied in polycythemia vera (Phase 2 RESTORE-PV) and sickle cell disease (Phase 1b).

The company is building out commercial capabilities ahead of a potential bitopertin launch. It is funded by roughly $683 million in cash and marketable securities as of September 30, 2026, plus about $486 million in net proceeds from an October 2026 offering, which management says provides runway into 2030. Updated Nov 5, 2026